ROBERT HUSEMANN: Open Payments
NPI 1013639749 · DUBUQUE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$803 in 53 payments from 14 companies in 2025. Trend: 2023 $793 · 2024 $1,303 · 2025 $803
Food & beverage: $803
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $191 |
| ABBVIE INC. | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Alkermes, Inc. | 4 | $72 |
| Supernus Pharmaceuticals, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Lundbeck LLC | 2 | $37 |
| HARMONY BIOSCIENCES LLC | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
Products named: INGREZZA, VRAYLAR, REXULTI, ARISTADA, Qelbree, CAPLYTA, AUSTEDO XR, UZEDY.
Industry payments across IA — which companies pay providers there.
